Form SC 13G ENANTA PHARMACEUTICALS Filed by: BlackRock Inc.
- Futures seesaw on bank worries, rate-hike pause hopes
- UBS to buy rival Credit Suisse in a deal worth over $3.2 billion
- European banks battered after Credit Suisse rescue
- First Republic Bank (FRC) selloff continues as S&P cuts rating again, says $30B infusion may not be enough
- Morgan Stanley’s Wilson says risk-reward in US equities remains unattractive, sees 15-20% downside risk
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Rese
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!